期刊文献+

脑卒中患者CYP2C19基因多态性与氯吡格雷抵抗相关性的研究进展

Research Progress in Correlation between CYP2C19 Gene Polymorphism and Clopidogrel Resistance in Stroke Patients
下载PDF
导出
摘要 脑卒中是常见的脑血管病,具有发病率高、致残率高、病死率高的特点。氯吡格雷是经典的抗血小板药物,其可有效预防脑卒中复发,亦是不能行溶栓治疗脑卒中患者的有效治疗药物,但部分患者不能从氯吡格雷临床应用中获益,出现氯吡格雷抵抗(CR)现象。CR的发生会影响氯吡格雷对脑卒中的治疗效果,严重者甚至会发生不良临床事件。CYP2C19基因多态性是影响CR发生最重要的内部因素,其可影响机体内氯吡格雷的代谢,进而影响其抗血小板作用。因此,CYP2C19基因多态性与CR的关系仍是未来的研究重点。 Stroke is a common cerebrovascular disease with high incidence,high disability rate and high mortality.Clopidogrel is a classic antiplatelet drug that can effectively prevent stroke recurrence and is also an effective treatment for stroke patients who cannot undergo thrombolytic therapy.However,some patients cannot benefit from the clinical application of clopidogrel,due to the phenomenon of clopidogrel resistance(CR).The occurrence of CR can affect the therapeutic effect of clopidogrel on stroke,and in severe cases,adverse clinical events may even occur.The CYP2C19 gene polymorphism is the most important internal factor affecting the occurrence of CR,which can affect the metabolism of clopidogrel in the body,thereby affecting its antiplatelet effect.Therefore,the relationship between CYP2C19 gene polymorphism and CR remains a focus of the future research.
作者 钟宇 李恺 刘义 ZHONG Yu;LI Kai;LIU Yi(Guangdong Provincial Key Laboratory of Research and Development of Natural Drugs,School of Pharmacy,Guangdong Medical University,Dongguan 523808,China;Pharmacy Intravenous Admixture Service,Meizhou People′s Hospital,Meizhou 514000,China)
出处 《医学综述》 CAS 2024年第1期13-18,共6页 Medical Recapitulate
关键词 脑卒中 CYP2C19基因 氯吡格雷抵抗 基因多态性 Stroke CYP2C19 gene Clopidogrel resistance Gene polymorphism
  • 相关文献

参考文献19

二级参考文献200

  • 1中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010[J].中国医学前沿杂志(电子版),2010,2(4):50-59. 被引量:1830
  • 2脑卒中患者临床神经功能缺损程度评分标准(1995)[J].中华神经科杂志,1996,29(6):381-383. 被引量:15736
  • 3Wong KS, Chen C, Fu J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cer- ebral or carotid artery stenosis ( CLAIR study) :a randomiscd,open-la- bel ,blinded-endpoint trial [ J ]. Lancet Neurol, 2010,9 ( 5 ) : 489 - 497. 被引量:1
  • 4Hochholzer W,Trenk D,Frundi D,ct al. Time dependence of platclet inhibition after a 600-rag loading dose of elopidogrel in a large, unse- lected cohort of candidates for percutaneous coronary intervention[ J]. Circulation,2005,111 (20) :2560 - 2564. 被引量:1
  • 5Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reac- tivity after clopidogrel administration on drug-eluting stent thrombosis [J]. J Am Coll Cardiol,2007,49(24) :2312 -2317. 被引量:1
  • 6Simon T, Verstuyft C ,Mary-Kraase M, et al. For [reach registry of a- cute ST-Elevation and Non-ST-Elevation myocardial infarction ( FAST- MI) investigators:genetic determinants of response to clopidogrel and cardiovascular events[ J]. N Engl J Med ,2009,360(4) :363 - 375. 被引量:1
  • 7Christoph V,Stefan J, David E,et al. Genetic variation of CYF2CI9 affects both phamlacokinetic and phmnacodynamic responses to clopi- dogrel but not prasugrel in aspirin-treated patients with coronary artery disease[J]. Eur Heart J,2009,30(14) :1744 -1752. 被引量:1
  • 8Rai M,Seip RL,Gupta A,et al. CYP2C19 genotype-guided antiplate- let therapy in a patient with clupidugrel resistance [ J]. Corm Med, 2012,76(5) :267 -272. 被引量:1
  • 9Par6 G,Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment [ J ]. N Engl J Med, 2010, 363 (18) :1704 - 1714. 被引量:1
  • 10U. S. Food and Drug Administration. FDA Drug Safety Communica- tion:Reduced effectiveness of plavix (clopidogrel)in patients who are poor metabolizers of the drug[ DB/OL]. 2010 [ 2010J)3-12 ]. http :/ /www. fda. gov/Drugs. 被引量:1

共引文献405

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部